P4O2 ILD Extension

Key facts

Sponsor

Amsterdam UMC, location VUmc

Principal Investigator

Esther Nossent, MD

Amsterdam UMC, locatie VUmc

Intervention

No Interventions(other)

Enrollment

450 enrolled

Eligibility

18-80 years · All sexes

Timeline

2024 – 2031

Study locations (1)

• Amsterdam UMC, locatie VUmc, Amsterdam, North Holland, Netherlands

Collaborators

AbbVie · Boehringer Ingelheim

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Hypersensitivity pneumonitis

Additional recruiting or active studies for the same condition.

• RECRUITINGNANCT06811389
  Reimagining Interventions for Support and Education in Hypersensitivity Pneumonitis
  Weill Medical College of Cornell University
• RECRUITINGNANCT03800017
  Skeletal Muscle Function in Interstitial Lung Disease
  University of British Columbia
• RECRUITINGNCT05549635
  Database and Biobank of Patients With Hypersensitivity Pneumonitis
  Nils Hoyer
• RECRUITINGEARLY PHASE1NCT05365802
  FAPI PET for Lung Fibrosis
  University of California, Los Angeles
• RECRUITINGNCT05392881
  Interstitial Lung Disease Research Unit Biobank
  University of Kansas Medical Center
• ACTIVE NOT RECRUITINGNCT04844359
  A Prognostic Transcriptomic Signature for Chronic Hypersensitivity Pneumonitis
  National Jewish Health
• ACTIVE NOT RECRUITINGNCT03747627
  BPF Genetics of ILD Study
  University of Dundee
• ENROLLING BY INVITATIONNCT04896138
  University of Virginia Natural History Study
  University of Virginia

See all trials for Hypersensitivity pneumonitis →